ヴェドリズマブの排泄はUCの重症度,低血清のヴェドリズマブ濃度および臨床応答率と関連している
Mark A Samaan1, Georgina Cunningham1, Samuel Hsiang Lim1
1Department of Gastroenterology, Guy's & St Thomas' Hospital.
Journal of Crohn's & colitis
|September 2, 2025
まとめ
活発な潰瘍性大腸炎 (UC) は,ヴェドリズマブの糞便の損失につながり,血清濃度と治療の有効性に影響します. この糞便の損失は病気の活性を示し,薬物の暴露を減少させ,患者の反応に悪影響を及ぼします.
科学分野:
- 胃腸内科
- 薬理学
- 炎症性腸疾患
背景:
- 潰瘍性大腸炎 (UC) は慢性炎症性腸疾患である.
- ベドリズマブは中等から重度のUCに使用される生物学的治療法です.
- 治療を最適化するために,UCにおけるヴェドリズマブの配置を理解することは極めて重要です.
研究 の 目的:
- UC患者におけるベドリズマブの排泄を調査する.
- 血清のヴェドリズマブ濃度に対する糞便の影響を測定する.
- 糞便の損失と治療結果の関係を評価する.
主な方法:
- ベドリズマブを投与開始したUC患者によるFAVOUR研究.
- 複数の時間点でのフェカル・ヴェドリズマブ濃度 (FVL) の測定
- 誘導療法中の低血清ベドリズマブ濃度 (SVL) の測定
主要な成果:
- 便中のヴェドリズマブは39%のサンプルで検出されました.
- FVLの上昇は,複数の時点での疾患の活動の増加と相関する.
- 14週に反応しなかった患者では,累積的なヴェドリズマブ流出が著しく高かった.
結論:
- アクティブUCは,ベドリズマブの有意な糞便損失と関連しています.
- 糞便の損失は,血清のヴェドリズマブ濃度が低下し,治療への反応が低下した.
- 病気が発現し,薬の効能が低下するバイオマーカーとして機能する.
さらに関連する動画
関連する概念動画
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
200
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
200
Inflammatory Bowel Disease I: Ulcerative Colitis
316
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
316
Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
238
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
238


